Search results
Showing 586 to 600 of 1240 results for pain
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Evidence-based recommendations on removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. This involves removing a small piece of ovarian tissue using keyhole surgery, freezing and storing it. After menopause starts, the tissue is thawed and transplanted under the skin of the armpit, abdomen or forearm, with the aim of producing oestrogen.
View recommendations for HTG640Show all sections
Transcutaneous electrical neuromuscular stimulation for urinary incontinence (HTG636)
Evidence-based recommendations on transcutaneous electrical neuromuscular stimulation for urinary incontinence in adults. This involves stimulating nerves and muscles in the pelvic floor to strengthen the muscles and reduce urine leaks.
View recommendations for HTG636Show all sections
Bioresorbable stent implantation to treat coronary artery disease (HTG633)
Evidence-based recommendations on bioresorbable stent implantation to treat coronary artery disease in adults. This involves implanting a stent (small tube) into a narrowed artery to widen it.
View recommendations for HTG633Show all sections
Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.
View recommendations for HTG75Show all sections
Sections for HTG75
Evidence-based recommendations on laparoscopic liver resection. This involves making small incisions (keyhole surgery) to remove the parts of the liver that are benign or cancerous.
View recommendations for HTG83Show all sections
Sections for HTG83
Evidence-based recommendations on cryotherapy for treating recurrent prostate cancer. This involves putting special needles or probes into the prostate and using Argon gas to freeze and destroy the cancerous prostate tissue.
View recommendations for HTG71Show all sections
Sections for HTG71
Self-expanding implant insertion into the intersphincteric space for faecal incontinence (HTG564)
Evidence-based recommendations on self-expanding implant insertion into the intersphincteric space for faecal incontinence. This involves inserting implants that expand and press together, forming a ring that creates an artificial sphincter.
View recommendations for HTG564Show all sections
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.
Laparoscopic gastric plication for the treatment of severe obesity (HTG293)
Evidence-based recommendations on laparoscopic gastric plication for the treatment of morbid obesity. This involves folding the stomach in on itself and stitching it together to reduce its volume.
View recommendations for HTG293Show all sections
Sections for HTG293
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
Evidence-based recommendations on laparoscopic techniques for hysterectomy. This involves surgically removing the uterus using special instruments through small cuts in the abdomen (keyhole surgery).
View recommendations for HTG153Show all sections
Sections for HTG153
Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids (HTG572)
Evidence-based recommendations on transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids in adults. This involves inserting a device through the cervix into the womb to destroy the fibroid using radiofrequency energy.
View recommendations for HTG572Show all sections
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.